Pricing
Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.
All price changes →More from Upanib
Other strengths and forms by Ziska Pharmaceuticals Ltd.
Indications & Uses
Upanib is indicated for:
Pharmacology
Upadacitinib is a Janus kinase (JAK) inhibitor. JAKs are enzymes inside the cell. They pass on signals that arise when cytokines or growth factors bind to their receptors on the cell membrane, and in this way they influence haematopoiesis and the function of immune cells. Along this signalling pathway, JAKs phosphorylate and activate the Signal Transducers and Activators of Transcription (STATs), which modulate activity inside the cell, including gene expression. Upadacitinib acts on the pathway at the level of the JAKs, so it prevents the phosphorylation and activation of STATs.
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Upadacitinib is given at different doses depending on the condition. For rheumatoid arthritis, the dose is 15 mg once daily. In psoriatic arthritis, adults 18 years of age and older also take 15 mg once daily. For atopic dermatitis, patients in the 12 kg to 65 kg group (weighing at least 40 kg) start with 15 mg once daily. If the response is not adequate, the dose may be increased to 30 mg once daily, and the medicine should be stopped if an adequate response is still not achieved at 30 mg. Adults 65 years of age and older take 15 mg once daily. In adult patients with ulcerative colitis, the induction dose is 45 mg once daily for 8 weeks, followed by a maintenance dose of 15 mg once daily. A dose of 30 mg once daily may be considered for patients with refractory, severe or extensive disease, and the medicine should be discontinued if an adequate therapeutic response is not achieved with 30 mg. Adult patients with Crohn's disease take 45 mg once daily for 12 weeks as induction, then 15 mg once daily for maintenance. Here too, 30 mg once daily may be considered for refractory, severe or extensive disease, and treatment should be discontinued if 30 mg does not give an adequate therapeutic response. For ankylosing spondylitis, the dose is 15 mg once daily. For non-radiographic axial spondyloarthritis, it is also 15 mg once daily. In polyarticular juvenile idiopathic arthritis, patients weighing 30 kg and greater take 15 mg once daily.
Side Effects
Upadacitinib side effects differ a little depending on the condition being treated. In rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and nonradiographic axial spondyloarthritis, the reactions seen in 1% or more of people were upper respiratory tract infections, herpes zoster, herpes simplex, bronchitis, nausea, cough, pyrexia, acne and headache. For atopic dermatitis, the reactions seen in 1% or more were upper respiratory tract infections, acne, herpes simplex, headache, raised blood creatine phosphokinase, cough, hypersensitivity, folliculitis, nausea, abdominal pain, pyrexia, increased weight, herpes zoster, influenza, fatigue, neutropenia, myalgia and influenza like illness. Ulcerative colitis: reactions reported in 5% or more during induction or maintenance were upper respiratory tract infections, increased blood creatine phosphokinase, acne, neutropenia, elevated liver enzymes and rash. Crohn's disease: reactions reported in 5% or more during induction or maintenance were upper respiratory tract infections, anemia, pyrexia, acne, herpes zoster and headache.
Cautions & Contraindications
Warnings & Precautions
Serious infections: don't use Upadacitinib in patients with an active, serious infection, and that includes localized infections. Malignancy: if a patient has a known malignancy, weigh the risks and benefits of Upadacitinib treatment before starting therapy. Thrombosis: weigh the risks and benefits before treating patients who may be at increased risk of thrombosis. If a patient has symptoms of thrombosis, evaluate them promptly and treat appropriately. Gastrointestinal perforations: use with caution in patients who may be at increased risk. Laboratory monitoring: this is recommended because lymphocytes, neutrophils, hemoglobin, liver enzymes and lipids may change. Embryo-fetal toxicity: based on animal studies, Upadacitinib may cause fetal harm. Females of reproductive potential should be told about the potential risk to a fetus and advised to use effective contraception. Vaccinations: avoid using Upadacitinib together with live vaccines.
Pregnancy & Breastfeeding
There isn't much human data on Upadacitinib in pregnant women, and what exists is not enough to tell whether the medicine raises the risk of major birth defects or miscarriage. Animal studies, though, show that upadacitinib could harm a developing baby. Women who are taking it should not breastfeed.
⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
Use in Special Populations
Pediatric Use: there are no data for children under 2 years.
Hepatic Impairment: Upadacitinib is not recommended in patients with severe hepatic impairment.
Renal Impairment: Patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis or polyarticular juvenile idiopathic arthritis need no dose adjustment with upadacitinib, even when renal impairment is mild to severe. In atopic dermatitis with severe renal impairment, the maximum dose is 15 mg once daily. Patients with ulcerative colitis or Crohn's disease and severe renal impairment should take 30 mg once daily for induction and 15 mg once daily for maintenance. Upadacitinib is not recommended in end-stage renal disease for atopic dermatitis, ulcerative colitis or Crohn's disease.
Overdose
In clinical trials, Upadacitinib was given at doses up to the equivalent of 60 mg extended-release once daily, measured as daily AUC. The adverse events at these doses were comparable to those seen at lower doses, and no specific toxicities were identified. Within the range of doses studied in clinical trials, approximately 90% of the Upadacitinib in the systemic circulation is eliminated within 24 hours of dosing. If someone takes an overdose, they should be monitored for signs and symptoms of adverse reactions. Anyone who develops adverse reactions should receive appropriate treatment.
⚠️ In an emergency call 999 or go to the nearest hospital emergency department.
Storage
Store Upadacitinib at a temperature no higher than 25°C, and keep it away from light. Keep it out of reach of children.
Drug Interactions
Common questions about Upanib 30 mg
What is Upanib 30 mg Tablet (Extended Release)?
Upanib 30 mg Tablet (Extended Release) is a medicine that contains Upadacitinib. It is made by Ziska Pharmaceuticals Ltd. It belongs to the Drugs used for Rheumatoid Arthritis group of medicines.
What is Upanib used for?
Upanib is used for: Inflammatory Bowel Disease, Rheumatoid Arthritis, Eczema, Inflammation.
What are the side effects of Upanib?
Upadacitinib side effects differ a little depending on the condition being treated. In rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and nonradiographic axial spondyloarthritis, the reactions seen in 1% or more of people were upper respiratory tract infections, herpes zoster, herpes simplex, bronchitis, nausea, cough, pyrexia, acne and headache.
Can I take Upanib during pregnancy or while breastfeeding?
There isn't much human data on Upadacitinib in pregnant women, and what exists is not enough to tell whether the medicine raises the risk of major birth defects or miscarriage. Animal studies, though, show that upadacitinib could harm a developing baby. Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
What happens if I take too much Upanib?
In clinical trials, Upadacitinib was given at doses up to the equivalent of 60 mg extended-release once daily, measured as daily AUC. The adverse events at these doses were comparable to those seen at lower doses, and no specific toxicities were identified. In an emergency call 999 or go to the nearest hospital emergency department.
How should I store Upanib?
Store Upadacitinib at a temperature no higher than 25°C, and keep it away from light. Keep it out of reach of children.
Can I take other medicines with Upanib?
Some medicines can interact with Upadacitinib, for example: Ketoconazole, Rifampicin. Tell your doctor or pharmacist about every medicine you take.
Is there a cheaper medicine with the same ingredient?
Upanib is already among the lowest-priced brands of Upadacitinib at this strength.
Do I need a prescription for Upanib?
Upanib is a prescription (Rx) medicine. Take it as your doctor advises.